Johnson & Johnson (JNJ): No More Worlds To Conquer
In a sign that it is still struggling as competition emerges for it major drugs Procrit and Risperdal and that its stent business is still troubled by safety concerns, Johnson & Johnson (JNJ) announced that it would buy back as…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
In a sign that it is still struggling as competition emerges for it major drugs Procrit and Risperdal and that its stent business is still troubled by safety concerns, Johnson & Johnson (JNJ) announced that it would buy back as much as $10 billion of its shares.
JNJ has a market cap of $186 billion. The announcement did not move the shares much. They inched up 1.5% to $63, and are down about 6% this year.
With 2006 revenue of $53 billion, its is a bit surprising that JNJ is not using the capital to buy another company. It is hard not to imagine that it pharma business could not benefit from the R&D at one or more of its smaller biotech partners.
But, it’s only $10 billion.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.




